The European Medicines Agency (EMA) has developed a three-year plan to formalize, structure and develop interactions with the academic community.
The European Medicines Agency (EMA) has developed a three-year plan to formalize, structure and develop interactions with the academic community.
“Academia plays an important role in helping the EU medicines regulatory network keep abreast of the opportunities and challenges brought by science, be it in the context of the development, assessment or safety monitoring of medicines,” noted EMA’s Executive Director Guido Rasi in a statement. “The framework will allow us to integrate cutting-edge scientific knowledge more tightly into our activities. It will also help academic start-ups benefit from advice from the EU regulatory network to translate their discoveries into patient-focused medicines.”
The framework’s objectives are to:
The framework builds on EMA’s experience in interacting with stakeholder associations representing patients and consumers, healthcare professionals and the pharmaceutical industry, continued the statement. The agency has also published a new web page for academia providing links to content that is likely to be of interest, and a section describing the way EMA interacts with academia, with more detail on the collaboration framework and action plan and useful resources for academics.
According to Prof. Piet H. van der Graaf, of the Leiden Academic Centre for Drug Research (LACDR) in The Netherlands, “This is an important step towards a strong alignment of the European excellence in regulatory and academic pharmaceutical sciences. In my discipline of systems pharmacology, I expect that this will act as a catalyst for new and better collaborations and cross-fertilisation in research, training and education. This should ultimately have a positive impact on the development of novel personalized medicines for patients.”
The dialogue between EMA and academia has already improved in time, but this is the perfect moment to structure this interaction and bring it to the next level, commented Dr. Rosa Giuliani, EU Policy Committee, European Society for Medical Oncology (ESMO).
“The framework of collaboration is a timely initiative, which is expected to fulfil specific tasks,” she said. “This is the platform needed to 1) promote regulatory awareness, 2) support academic research and 3) boost communication between the two parties. Now it is time to work!”
To view the full release, click herePhilip Ward is the European Editor for Applied Clinical Trials
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.